ERBB2 and colorectal cancer: Based on this, a single-arm, open-label, multiple centers, prospective study of Disitamab Vedotin combined with Tislelizumab in HER2-positive advanced colorectal cancer failed at least two lines of systemic treatment are ongoing in our hospital (NCT05493683).